Literature DB >> 3653849

Hepatic encephalopathy: lack of changes of gamma-aminobutyric acid content in plasma and cerebrospinal fluid.

F Moroni1, O Riggio, V Carlà, V Festuccia, F Ghinelli, I R Marino, M Merli, L Natali, G Pedretti, F Fiaccadori.   

Abstract

The aim of the study was to verify the role of gamma-aminobutyric acid in the pathogenesis of hepatic encephalopathy occurring in cirrhotic patients by attempting to correlate plasma and cerebrospinal fluid content of authentic gamma-aminobutyric acid with the neurological manifestations of hepatic encephalopathy. For this purpose, plasma and cerebrospinal fluid gamma-aminobutyric acid levels were measured by means of mass fragmentography in 17 cirrhotic patients with hepatic encephalopathy and in 6 cirrhotics without neurological symptoms. Moreover, in all patients, a second sample was obtained during the clinical course of hepatic encephalopathy. The mean plasma and cerebrospinal fluid gamma-aminobutyric acid levels were not different in patients with or without hepatic encephalopathy and did not change during the evolution of the neurological symptoms. The lack of changes in the gamma-aminobutyric acid content in plasma and cerebrospinal fluid during hepatic encephalopathy is in contrast with the hypothesized importance of increased entry into the brain of gamma-aminobutyric acid in the pathogenesis of hepatic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3653849     DOI: 10.1002/hep.1840070504

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

Review 1.  Pathogenesis and treatment of portal-systemic encephalopathy: an update.

Authors:  R F Butterworth
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

Review 2.  Neurochemistry of hepatic encephalopathy.

Authors:  C O Record
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

3.  Cerebrospinal fluid amino acids in relation to neurological status in experimental portal-systemic encephalopathy.

Authors:  G Therrien; R F Butterworth
Journal:  Metab Brain Dis       Date:  1991-06       Impact factor: 3.584

Review 4.  Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 5.  The role of inhibitory amino acidergic neurotransmission in hepatic encephalopathy: a critical overview.

Authors:  Jan Albrecht; Magdalena Zielińska
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

6.  Reduced expression of astrocytic glycine transporter (Glyt-1) in acute liver failure.

Authors:  Claudia Zwingmann; Paul Desjardins; Alan Hazell; Nicolas Chatauret; Adriana Michalak; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

7.  Benzodiazepine-like substances and hepatic encephalopathy : implications for treatment.

Authors:  J A Cossar; P C Hayes; R E O'Carroll
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

8.  Loss of [3H]MK801 binding sites in brain in congenital ornithine transcarbamylase deficiency.

Authors:  L Ratnakumari; I A Qureshi; R F Butterworth
Journal:  Metab Brain Dis       Date:  1995-09       Impact factor: 3.584

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.